Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update for an anti-CD38 antibody drug conjugate in relapsed or refractory multiple myeloma spanning Phase 1 and Phase 2, cu…
-
CLINICAL_TRIALS trial_result · 2023-04-07Clinical Trial Update: The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of adding colchicine to conventional therapy for multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-04-04Clinical Trial Update: Expanded Natural Killer (NK) Cells for Multiple Myeloma Study [Phase 1, Phase 2]
Phase 1/2 study investigating expanded natural killer (NK) cells for multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: Pedometer Activity Monitoring After ASCT [Phase 2]
Phase 2 clinical trial evaluating pedometer-based activity monitoring after autologous stem cell transplantation in lymphoma and myeloma pat…
-
CLINICAL_TRIALS trial_result · 2023-03-27Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma [Phase 3]
Phase 3 trial evaluating nivolumab, pomalidomide, and dexamethasone in multiple myeloma has completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone [Phase 1]
Phase 1 trial update for M3258 (saracatinib-like investigational) in single agent and combination with dexamethasone in multiple myeloma; st…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ipilimumab after stem cell transplantation in relapsed/refractory multiple myeloma was terminated, with results…
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 trial evaluating INCB001158 with subcutaneous daratumumab versus daratumumab SC alone in relapsed or refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma [NA]
A completed clinical trial evaluating an amino acid mixture (Enterade) used during high-dose melphalan conditioning prior to autologous stem…
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function [Phase 2]
Phase 2 clinical trial assessing pharmacokinetics of melphalan during treatment with melflufen and dexamethasone in patients with relapsed/r…
-
CLINICAL_TRIALS trial_result · 2023-03-07Clinical Trial Update: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial exploring APG-2575 as monotherapy or in combination with lenalidomide or DXMS in relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) [Phase 2]
Phase 2 MATCH subprotocol Z1F investigates copanlisib for cancers with PIK3CA mutations. Results (posted 2023-02-28) pertain to participants…
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant [Phase 2]
Phase 2 trial comparing generic pegfilgrastim to brand-name pegfilgrastim for neutrophil recovery after autologous transplantation.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating cobimetinib alone or with venetoclax, with or without atezolizumab, in relapsed/refractory multiple myeloma; stud…
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM [Phase 2]
A Phase 2 clinical trial evaluating selinexor in combination with an immunomodulator (thalidomide/pomalidomide/lenalidomide) for relapsed/re…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) [Phase 1, Phase 2]
Phase 1/2 trial evaluating TAK-079 as a single-agent subcutaneous therapy for relapsed/refractory multiple myeloma completed with posted res…
-
CLINICAL_TRIALS trial_result · 2023-02-23Clinical Trial Update: Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma [Phase 3]
Phase 3 trial assessing lenalidomide plus dexamethasone in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2023-02-23Clinical Trial Update: Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating safety and efficacy of anti-GPRC5D CAR-T cells for relapsed/refractory multiple myeloma. Details on re…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma [Phase 2]
Phase 2 clinical trial update for KRN125 in patients with multiple myeloma and malignant lymphoma has been completed.
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating the safety and efficacy of durvalumab in combination with daratumumab for relapsed/refractory multiple myeloma; stu…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for a BCMA CAR-T cell therapy in newly diagnosed multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-02-17Clinical Trial Update: Prolonged Protection From Bone Disease in Multiple Myeloma [Phase 4]
Phase 4 clinical trial update reporting prolonged protection from bone disease in patients with multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2023-02-13Clinical Trial Update: Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients [Phase 3]
A Phase 3 multinational trial comparing isatuximab, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) [Phase 2]
Phase 2 study of the IDd regimen (ixazomib, daratumumab, dexamethasone) in relapsed/refractory multiple myeloma has completed enrollment and…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention [Phase 3]
Phase 3 trial comparing Tacrolimus plus mini-methotrexate versus Tacrolimus plus methotrexate for graft-versus-host disease prevention has c…